



CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

August 28, 2007 Boris H. Smith
Date Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Robert F. GARRY
Russell B. WILSON

Serial No.: 10/578,013

Filed: May 3, 2006

For: **METHOD OF PREVENTING VIRUS:CELL
FUSION BY INHIBITING THE FUNCTION
OF THE FUSION INITIATION REGION IN
RNA VIRUSES HAVING CLASS 2
MEMBRANE FUSOGENIC ENVELOPE
PROTEINS**

§ Confirmation No.: 3051

§

§ Group Art Unit: 1648

§

§ Examiner: Nicole Kinsey

§

§ Atty. Dkt. No.: 12920.0013.PCUS00

§

§

§

§

§

§

§

§

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the examiner and made of record. Copies of documents B3, B4 and C4-C7 are attached, as well as copies of two Supplemental Partial Search

Reports, dated May 21, 2007 and July 30, 2007, respectively, issued for the European counterpart of this application.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b)(3). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Deposit Account No. 08-3038/12920.0013.PCUS00.

Respectfully submitted,



Dennis R. Chesire
Reg. No. 57,452
Agent for Assignee
THE ADMINISTRATORS OF THE
TULANE EDUCATIONAL FUND

Customer No. 23369
HOWREY LLP
1111 Louisiana, 25th Floor
Houston, Texas 77002
(713) 787 1400

Date: August 28, 2007

Form PTO-1449 (modified)

Atty. Docket No.
12920.0013.PCUS00Serial No.
10/578,013

List of Patents and Publications for Applicant's

Applicant
Robert F. Garry, Russell B. Wilson

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
May 3, 2006Group:
1648U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Pages 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						
	A2						
	A3						
	A4						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B3	WO 01/59457 A2	08/16/2001	WIPO	G01N	33/569	
	B4	WO 88/08429	11/03/1988	WIPO	C07K	7/08	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C4	CHAN, et al., Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target, (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95 , 15613-15617.
	C5	CARR, et al., A spring-loaded mechanism for the conformational change of influenza hemagglutinin, (1993). <i>Cell</i> 73 , 823-832.
	C6	FASS, et al., Dissection of a retrovirus envelope protein reveals structural similarity to influenza hemagglutinin, (1995). <i>Current Biology</i> 5 , 1377-1383.
	C7	CLEGG, et al., Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products, (1991). <i>Virus Research</i> 18 , 151-164.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

DM_US:20636446_1

